Search - tctmd.com

Displaying 161 - 180 of 216

Sort: Relevancy | Date

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

Presentation EuroPCR 2018

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

Presenter: David E. Kandzari

May 23, 2018

News Industry News

ReCor Medical To Release of Clinical Trial Results 23 May at EuroPCR in Paris

May 17, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

News Daily News

Prominent Investigator Takes Post at Medtronic as Pivotal Renal Denervation Trial Is Announced

Todd Neale

April 12, 2018

News Industry News

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

April 09, 2018

Presentation Controversies and Advances 2017

Rise, Fall And Resurrection of Renal Denervation

Presenter: Michael A. Weber

November 16, 2017

Presentation TCT 2017

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Presenter: Hiren Mistry, Michael A. Weber

October 31, 2017

Presentation TCT 2017

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Presenter: Hiren Mistry, Michael A. Weber, Michael Böhm

October 31, 2017

Presentation TCT 2017

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

Presenter: Elazer R. Edelman, Paul A. Sobotka, Karl-Heinz Kuck

October 30, 2017

Presentation TCT 2017

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Presenter: Elazer R. Edelman, Paul A. Sobotka, Krishna J. Rocha-Singh

October 30, 2017

Presentation TCT 2017

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

Presenter: Elazer R. Edelman, Paul A. Sobotka

October 30, 2017

Presentation TCT 2017

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Presenter: Michael Böhm, Thomas F. Luscher, Robert S. Schwartz

October 30, 2017

Presentation TCT 2017

Diagnostic Mapping and Functional Assessment of the Renal Nerves: The Pythagoras Device

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Alcohol-Mediated Renal Denervation With a Higher-Dose: From the European Registry to Target BP 1

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Vessix RE-INFORCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Laura Mauri

October 30, 2017

Presentation TCT 2017

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

Presenter: Michael Böhm, Thomas F. Luscher, Melvin D. Lobo

October 30, 2017

Presentation TCT 2017

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

Presenter: Michael Böhm, Thomas F. Luscher

October 30, 2017

Advertisement

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

ReCor Medical To Release of Clinical Trial Results 23 May at EuroPCR in Paris

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Prominent Investigator Takes Post at Medtronic as Pivotal Renal Denervation Trial Is Announced

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

Rise, Fall And Resurrection of Renal Denervation

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Diagnostic Mapping and Functional Assessment of the Renal Nerves: The Pythagoras Device

Alcohol-Mediated Renal Denervation With a Higher-Dose: From the European Registry to Target BP 1

Vessix RE-INFORCE Trial Update

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content